77-Year-Old Lung Cancer Patient Appeals for Subsidized Drugs After Costly Treatment Ordeal
SingTao · 1 SOURCESabout 2 hours ago2 MIN
Summary
Lung cancer remains the leading cause of cancer death in Hong Kong, accounting for 3,782 deaths in 2022—representing 25.7% of all cancer fatalities . A 77-year-old patient, known as Silver Sister, was diagnosed with Stage 4 HER2-mutant lung cancer in 2024 after experiencing fluid buildup in her lungs. With doctors estimating her life expectancy at just six months to one year, she faced an impossible choice: the recommended targeted drug therapy would cost hundreds of thousands of Hong Kong dollars annually, far beyond her means . After learning that a charitable organization could help patients access treatment in mainland China where some medications are cheaper, Silver Sister decided to try cross-border care despite her fears .
Key Points
- Silver Sister, 77, was diagnosed with Stage 4 HER2 lung cancer in 2024 with fluid in her lungs and given 6-12 months to live
- Annual targeted drug costs reach several hundred thousand Hong Kong dollars, making treatment unaffordable for the patient
- She experienced severe side effects in mainland China including fever, dizziness, vomiting, and extreme weakness preventing her from getting out of bed
- HER2-mutant lung cancer, while relatively uncommon, progresses rapidly with limited treatment options currently available in Hong Kong
- Two drug classes—antibody-drug conjugates (ADC) and oral tyrosine kinase inhibitors (TKI)—are approved in Hong Kong but not yet covered under the Hospital Authority Drug Formulary
Why It Matters
The case highlights critical gaps in Hong Kong's cancer care system. With lung cancer claiming approximately 3,782 lives annually in Hong Kong, many patients face impossible choices between financial ruin and inadequate treatment . Patient advocates emphasize that delaying or missing treatment opportunities due to unaffordable medications can significantly worsen outcomes, while also noting the substantial psychological and caregiving burdens borne by patients and their families .
The case highlights critical gaps in Hong Kong's cancer care system. With lung cancer claiming approximately 3,782 lives annually in Hong Kong, many patients face impossible choices between financial ruin and inadequate treatment . Patient advocates emphasize that delaying or missing treatment opportunities due to unaffordable medications can significantly worsen outcomes, while also noting the substantial psychological and caregiving burdens borne by patients and their families .